Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1981-10-25
pubmed:abstractText
The results of a national clinical trial to compare combination and sequential chemotherapy for stage III or IV ovarian cancer are reported. Of the 253 patients from 16 centres across Canada who were admitted to the trial 13 were excluded from the analysis. All the patients were observed for 2 to 5 years from entry into the trial. There were no differences in response to therapy or in survival between the patients treated with melphalan followed by 5-fluorouracil and then by methotrexate in high dosage and the patients treated with the same agents in combination. Patients with minimal residual disease after resection of stage III ovarian cancer had a good prognosis. Other favourable prognostic factors were age (less than 55 years), performance status (90% or 100% on the Karnofsky scale) and histologic grade of the tumour.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/7020903-101843, http://linkedlifedata.com/resource/pubmed/commentcorrection/7020903-109198, http://linkedlifedata.com/resource/pubmed/commentcorrection/7020903-109202, http://linkedlifedata.com/resource/pubmed/commentcorrection/7020903-13861733, http://linkedlifedata.com/resource/pubmed/commentcorrection/7020903-14268035, http://linkedlifedata.com/resource/pubmed/commentcorrection/7020903-376134, http://linkedlifedata.com/resource/pubmed/commentcorrection/7020903-376135, http://linkedlifedata.com/resource/pubmed/commentcorrection/7020903-376136, http://linkedlifedata.com/resource/pubmed/commentcorrection/7020903-4098756, http://linkedlifedata.com/resource/pubmed/commentcorrection/7020903-4189962, http://linkedlifedata.com/resource/pubmed/commentcorrection/7020903-4316665, http://linkedlifedata.com/resource/pubmed/commentcorrection/7020903-4541737, http://linkedlifedata.com/resource/pubmed/commentcorrection/7020903-4962186, http://linkedlifedata.com/resource/pubmed/commentcorrection/7020903-4966488, http://linkedlifedata.com/resource/pubmed/commentcorrection/7020903-5088208, http://linkedlifedata.com/resource/pubmed/commentcorrection/7020903-5637955, http://linkedlifedata.com/resource/pubmed/commentcorrection/7020903-5644296, http://linkedlifedata.com/resource/pubmed/commentcorrection/7020903-5647240, http://linkedlifedata.com/resource/pubmed/commentcorrection/7020903-5847906, http://linkedlifedata.com/resource/pubmed/commentcorrection/7020903-5892067, http://linkedlifedata.com/resource/pubmed/commentcorrection/7020903-6041727, http://linkedlifedata.com/resource/pubmed/commentcorrection/7020903-831755, http://linkedlifedata.com/resource/pubmed/commentcorrection/7020903-947531
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0008-4409
pubmed:author
pubmed:issnType
Print
pubmed:day
6
pubmed:volume
123
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
365-71
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1980
pubmed:articleTitle
Combination v. sequential therapy with melphalan, 5-fluorouracil and methotrexate for advanced ovarian cancer.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Controlled Clinical Trial